TuHURA Biosciences initiated with a Buy at Rodman & Renshaw

Rodman & Renshaw initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $11 price target TuHURA is focused on developing treatments to overcome primary and acquired resistance to checkpoint inhibitors by using its proprietary technology platform, Immune FxTM, the analyst tells investors in a research note. The firm says the company’s strategy leverages bacterial proteins to activate the immune system avoids common issues like the toxicity and infections often linked to using attenuated bacteria for cancer therapy.